Image
19.06.2024
Cost of devastating complications highlights urgent need to transform ...
Devastating diabetes complications costs the UK healthcare system £6.2 billion a year, which highlights n...
customer support
customer support
From research findings supporting SGLT-2 inhibitors as a first-choice type 2 treatment to a real-world study strengthening evidence for teplizumab in early type 1, here are some of the diabetes research developments announced in February 2026.
Read more